Tuesday, 19 October 2021

Covaxin gets approval for children aged 2-18 years

Covaxin gets approval for children aged 2-18 years

The immunogenicity and safety of India's Covid-19 vaccine Covaxin are almost the same in children as in adults of more than 18 years of age, reported news agency ANI an AIIMS professor.

Dr. Sanjay K Rai, a professor at a Centre for Community Medicine, AIIMS, said

"Covaxin's test was done on three age category. The first category examined was between aged 12 -18 years, the second group was between aged 6- 12 years and the third aged group was between 2-6 years,"

Notably, Rai was the principal investigator of Covaxin trials on children.

The doctor said

"At first, we finished the examination of people aged between 12- 18 years and then subsequently other groups. Covaxin's vaccine safety and immunogenicity are almost the same. However, the final results of these trials are awaited. We had already carried out trials on the adult population. For children, we are waiting for the results,"

Covaxin gets approval for children aged 2 18 years 1unsplash image

Read More: Final Decision on Covaxin by WHO in next week

Rai noted that globally it is observed that SARS-CoV-2 isn't fatal in children.

He said.

"Only a very mild infection is present. In a few children, it's milder than the common cold. Currently, we don't have any justification on whether Zydus Cadila, Bharat Biotech, Pfizer or Moderna...which is the mildest. These vaccines are reducing the severity of the infection but not the infection,"

These come even as AIIMS chief Dr. Randeep Guleria said earlier this month that children between 12 to 18 would be vaccinated against Covid-19 very soon, adding that the current priority is to immunize those who can have severe diseases.

He said.

"As we know that children mostly have gentle diseases, so due to the limited supply of the vaccination, we are prioritising those people who can have severe disease,"

Meanwhile, WHO (World Health Organisation) experts will meet this week to take the final decision on whether to grant emergency use listing to Covaxin-- an inactivated whole virion vaccine.

Follow Us

Popular Post